

Oral Antibiotics for Non-operative Treatment of Community-Acquired Appendicitis and Diverticulitis

These guidelines provide oral antibiotic recommendations for patients with minimal healthcare exposure experiencing acute uncomplicated appendicitis or diverticulitis for whom non-operative management has been selected by the clinician.

- Empiric antimicrobial therapy should cover the most likely organisms to cause intra-abdominal infections including Gram-negative Enterobacterales, aerobic streptococci, and obligate enteric anaerobes
- Resistance rates of *E. coli* and *Bacteroides* spp. to commonly used antibiotics have been globally increasing
- The typical antibiotic course is 5-7 days, either initiated with oral therapy or following a brief IV course
- Infectious Disease or ADSP consultation is recommended for immunocompromised hosts, patients with recent antibiotic use, or those with a history of infection or colonization with antibiotic resistant organisms such as *Pseudomonas aeruginosa*, ESBL-producing Enterobacterales, or *Enterococcus* spp.
- Due to the lack of data suggesting superiority of one oral antibiotic regimen over others, the following antibiotic recommendations are based on the Surgical Infection Society guidelines, literature review, and local susceptibility patterns

Antibiotic Recommendations		
First-line	Cephalexin 1000 mg PO q8h1 + metronidazole 500 mg PO q12h	
Alternative if contraindication or severe or life-	(Ciprofloxacin 500 mg PO q12h1 or levofloxacin 500 mg	
threatening allergy ² to above	PO q24h ¹) + metronidazole 500 mg PO q12h	
Alternative if unable to tolerate metronidazole	Moxifloxacin 400 mg PO q24h ³	

¹ Consult package insert or pharmacist for renal dose adjustment if patient has renal dysfunction: renal dose adjustments

³ Alternative due to increasing rates of anaerobic resistance

Antibiotic	Inpatient <i>E. coli</i> Susceptibility ¹	Cost for 5d Course ²
Amoxicillin-clavulanate	54-67%	\$4-\$17
Cefpodoxime ³	84%	\$15-\$31
Cefuroxime ³	84%	\$4-\$31
Cephalexin	78-80%	\$3-\$15
Ciprofloxacin	69-74%	\$5-\$15
Levofloxacin	64-75%	\$6-\$28
Moxifloxacin (Non-formulary)	70%	\$7-\$38
TMP-SMX	69-72%	\$3-\$8

¹ Based on NM Inpatient Antibiogram from 6/23/2021-6/24/2022

Last Updated: February 2023

² Refer to β-lactam cross-reactivity chart to assess if alternate β-lactam is safe to use: cross reactivity chart or contact ADSP pharmacist

² Cost data obtained from GoodRx (assuming patient has no insurance coverage or antibiotic is not covered by insurance)

³ Less preferred due to limited accessibility in community pharmacies, increased costs, and potential drug interaction with acid suppressing medications